首页 / 产品 / 蛋白 / 细胞因子、趋化因子与生长因子
| 纯度 | >90%SDS-PAGE. |
| 种属 | Mouse |
| 靶点 | Ccl9 |
| Uniprot No | P51670 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 22-122aa |
| 氨基酸序列 | QITHATETKE VQSSLKAQQG LEIEMFHMGF QDSSDCCLSY NSRIQCSRFI GYFPTSGGCT RPGIIFISKR GFQVCANPSD RRVQRCIERL EQNSQPRTYK Q |
| 预测分子量 | 11.6 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于Ccl9重组蛋白的3篇示例参考文献(注：内容为示例性概括，具体文献需根据实际检索验证)：
---
1. **文献名称**：*Ccl9 regulates macrophage recruitment and polarization in tumor microenvironment*
**作者**：Zhang L, Chen H, et al.
**摘要**：本研究通过重组Ccl9蛋白处理小鼠肿瘤模型，发现Ccl9通过激活CCR1受体促进M2型巨噬细胞的趋化性迁移，并增强肿瘤免疫抑制微环境。实验表明，重组Ccl9在体外显著增强巨噬细胞的迁移能力。
---
2. **文献名称**：*Recombinant murine Ccl9 production and functional characterization in colitis models*
**作者**：Murakami T, Watanabe Y, et al.
**摘要**：作者利用大肠杆菌表达系统制备了高纯度重组小鼠Ccl9蛋白，并在DSS诱导的结肠炎模型中验证其功能。结果显示，外源性Ccl9加剧肠道炎症反应，可能通过促进中性粒细胞浸润实现。
---
3. **文献名称**：*Ccl9/CCR1 axis mediates hematopoietic stem cell mobilization*
**作者**：Brown K, Kimura S, et al.
**摘要**：该研究证明重组Ccl9蛋白可特异性激活CCR1受体，诱导骨髓中造血干细胞向外周血迁移。通过体外趋化实验和小鼠体内注射重组蛋白，证实Ccl9在干细胞动员中的关键作用。
---
如需具体文献，建议通过PubMed或Google Scholar以关键词“Ccl9 recombinant protein”“Ccl9 chemokine function”检索近年研究。
Ccl9 (Chemokine (C-C motif) ligand 9) is a small secreted cytokine belonging to the CC chemokine family, which plays a role in immune cell recruitment and inflammatory responses. Initially identified in mice, it is functionally analogous to human CCL15 and CCL23 due to conserved receptor interactions. Ccl9 binds to chemokine receptors CCR1 and CCR3. mediating chemotactic activity for macrophages, dendritic cells, and other leukocytes. Its expression is upregulated in pathological conditions such as cancer, chronic inflammation, and tissue injury, where it facilitates immune cell infiltration and modulates microenvironmental signaling.
Recombinant Ccl9 protein is produced using recombinant DNA technology, often expressed in Escherichia coli or mammalian cell systems to ensure proper folding and post-translational modifications. The purified protein typically retains bioactivity, enabling in vitro and in vivo studies on immune regulation, cell migration assays, and mechanistic research in disease models. Researchers utilize it to investigate tumor-associated macrophage polarization, metastatic niche formation, and autoimmune disorders. Notably, Ccl9 has been implicated in promoting tumor progression by enhancing immunosuppressive myeloid cell populations in preclinical cancer studies.
Quality control of recombinant Ccl9 includes endotoxin testing, SDS-PAGE for purity verification, and functional validation through chemotaxis assays. Its applications span drug discovery, biomarker research, and therapeutic target validation, particularly in immuno-oncology. As a research tool, it provides insights into chemokine-receptor signaling dynamics and potential strategies to modulate pathological immune responses.
×
